Hudson Bay Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Hudson Bay Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-606,808	Closed	-$80.1M	–	1755
2025 Q1	$80.1M	Buy	606,808 +541,759	+833%	+$67.5M	0.25%	96
2024 Q4	$5.43M	Sell	65,049 -14,951	-19%	-$1.23M	0.02%	488
2024 Q3	$5.85M	Sell	80,000 -25,000	-24%	-$1.88M	0.02%	386
2024 Q2	$7.19M	Buy	105,000 +75,000	+250%	+$5.2M	0.03%	306
2024 Q1	$2.08M	Buy	30,000 +5,000	+20%	+$344K	0.01%	447
2023 Q4	$1.79M	Sell	25,000 -10,000	-29%	-$575K	0.01%	468
2023 Q3	$1.82M	Buy	+35,000	New	+$2.04M	0.01%	494
2020 Q3	–	Sell	-20,000	Closed	-$513K	–	644
2020 Q2	$513K	Sell	20,000 -111,036	-85%	-$2.25M	0.01%	410
2020 Q1	$2.01M	Buy	+131,036	New	+$2.85M	0.05%	264

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Hudson Bay Capital Management's ITCI Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 606,808 shares — an estimated $80.1M sold.

Hudson Bay Capital Management first reported a position in ITCI in Q1 2020 and held it in 9 quarters. The position peaked at $80.1M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Hudson Bay Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 606,808 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $80.1M.
Hudson Bay Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 9 quarters.
Hudson Bay Capital Management's Intra-Cellular Therapies Inc. position peaked at $80.1M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.